Article · Health news

MHRA approves Wegovy for liver disease

Health news Published · sources checked

The MHRA approved Wegovy (semaglutide) on 3 July 2026 for MASH, a form of liver disease, in adults with moderate-to-advanced liver fibrosis.

Key points

  • The MHRA approved Wegovy (semaglutide) on 3 July 2026 for MASH in adults with moderate-to-advanced liver fibrosis.
  • The approval is conditional on further results from an ongoing study being submitted.
  • The announcement says people with MASH cannot yet get semaglutide for this condition on the NHS.

What was announced

The MHRA says it has approved Wegovy (semaglutide) for MASH in adults with moderate-to-advanced liver fibrosis. MASH (metabolic dysfunction-associated steatohepatitis) is a form of liver disease.

Conditions of the approval

The approval is conditional: the company must submit further results from an ongoing study in adults with MASH and moderate to advanced liver scarring. The announcement states that people with MASH cannot yet get semaglutide for this condition on the NHS.

More guides and news

Educational content. This article summarises public guidance and announcements in plain English for education. It is not medical advice and it cannot say what is right for you: speak to a clinician about your own health, call NHS 111 if you are unsure what to do and 999 in an emergency.